Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 14;4(10):100575.
doi: 10.1016/j.jtocrr.2023.100575. eCollection 2023 Oct.

Initial Steps in Creating a Patient-Centric Addendum to Clinical Trial Informed Consent Forms

Bellinda L King-Kallimanis  1 , Andrea Ferris  1 , Lisa Dropkin  2 , Mariel Molina  2 , Lydia Redway  2 , David E Gerber  3 , Tracey L Grant  1 , Upal Basu Roy  1
Affiliations

Initial Steps in Creating a Patient-Centric Addendum to Clinical Trial Informed Consent Forms

Bellinda L King-Kallimanis et al. JTO Clin Res Rep. .

Abstract

Introduction: The purpose of the informed consent form (ICF) is to outline the risks and benefits of an interventional clinical trial to potential participants. The aim of this study was to explore the feasibility of a short addendum to the ICF, summarizing key points most relevant to potential participants.

Methods: A sample of 20 ICFs was reviewed against the requirements of the U.S. federal regulation documents and assessed for readability. Alongside the ICF review, we conducted focus groups and one-on-one interviews with people with lung cancer (n = 9) to learn what information was most important when considering participation in a clinical trial using a hypothetical phase 3 ICF.

Results: The 20 ICFs reviewed were from phases 1 to 3, expanded-access, and single-patient trials covering predominantly NSCLC; 60% were global. The mean length of the ICFs was 21 (range: 15-34) pages. The average reading level was tenth grade whereas the average U.S. reading level was eighth grade. Readability varied by section, the "purpose of the study" section had the highest reading level. In the qualitative research component, participants were "overwhelmed" by the hypothetical ICF. Participants were also asked to list information for the addendum; their suggestions broadly map to federal regulations. An addendum with reference to sections in the ICF for additional details was well received.

Conclusions: The variations in ICF architecture and readability make it difficult for patients to make an informed decision to participate in a clinical trial. Implications extend beyond lung cancer, highlighting key areas for ICF improvements and providing a roadmap for developing a patient-centric addendum.

Keywords: Clinical trials; Informed consent forms; Lung Cancer; Patient-focused drug development.

PubMed Disclaimer

References

    1. Getz K.A., Campo R.A. New benchmarks characterizing growth in protocol design complexity. Drug Inf J. 2018;52:22–28. - PubMed
    1. Informed consent information sheet: guidance for IRBs, clinical investigators, and sponsors. Draft Guidance. https://www.fda.gov/media/148810/download
    1. Jefford M., Moore R. Improvement of informed consent and the quality of consent documents. Lancet Oncol. 2008;9:485–493. - PubMed
    1. Kim E.J., Kim S.H. Simplification improves understanding of informed consent information in clinical trials regardless of health literacy level. Clin Trials. 2015;12:232–236. - PubMed
    1. Schaeffer M.H., Krantz D.S., Wichman A., Masur H., Reed E., Vinicky J.K. The impact of disease severity on the informed consent process in clinical research. Am J Med. 1996;100:261–268. - PubMed

LinkOut - more resources